Results 101 to 110 of about 28,581 (233)

Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope

open access: yes, 2002
The tumor-associated autoantigen MUC1 is intensively studied as a potential target for antigen-specific immunotherapy of cancer. Previous reports concerning experiments in preclinical murine tumor models have provided evidence Supporting the feasibility ...
Heukamp, L C   +6 more
core   +1 more source

Self‐Assembly of Therapeutic Peptides for Enhanced Cancer Therapy: Strategies, Therapeutic Performance, and Future Perspectives

open access: yesMedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Therapeutic peptide self‐assembly is governed by multiple non‐covalent interactions, enabling the construction of diverse supramolecular structures. These self‐assembled systems can be engineered through spontaneous self‐assembly of monomers, co‐assembly, or stimulus‐responsive strategies to improve tumor delivery efficiency.
Yuelin Fang   +6 more
wiley   +1 more source

MUC1.Tg mice appeared to elicit MUC1-specific peripheral tolerance.

open access: yes, 2013
T cells from mice vaccinated with MUC1 DNA or T cells from mice immunized with control vectors (3×106 cells) were mixed with B16-F10-MUC1 cells (5×104 cells) and subcutaneously injected into naïve B6 or MUC1.Tg mice. Survival rates of the mice are shown.
Shigenori Nagai (307307)   +6 more
core   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

INDICATORS OF MUC 5AC AND MUC 1 MUCOPOLYSACCHARIDE EXPRESSION IN THE NASAL MUCOSA OF PATIENTS WITH POSTNASAL DRIP SYNDROME AND NASAL SEPTUM DEVIATION

open access: yesКлінічна та профілактична медицина
Introduction. Determining the cause of postnasal drip syndrome can be quite challenging. Nasal septum deformation has been recognized as one possible factor.
Nataliia V. Babchenko   +3 more
doaj   +1 more source

The microbiome and brain metastasis in non‐small cell lung cancer: A graded appraisal and a framework for prevention‐oriented research

open access: yesClinical and Translational Medicine, Volume 16, Issue 11, November 2026.
This Review proposes a microbiome–premetastatic brain niche axis connecting gut, lung, and intratumoral microbes with metabolites, blood–brain barrier remodeling, neuroimmune priming, and brain metastasis in NSCLC. It integrates current evidence while distinguishing established mechanisms from associations and hypotheses requiring prospective and ...
Long Liang   +8 more
wiley   +1 more source

Chemopreventive Effect of Bitter Melon (Momordica charantia) Juice on Pancreatic Carcinogenesis in LSL‐KrasG12D/+; p48Cre/+ Mice

open access: yesMolecular Carcinogenesis, Volume 65, Issue 11, Page 1383-1397, November 2026.
ABSTRACT Herein, using the LSL‐KrasG12D/+; p48Cre/+ transgenic mouse model [that recapitulates the full spectrum of human disease, progressing from early pancreatic intraepithelial neoplasia lesions to invasive pancreatic ductal adenocarcinoma (PDAC)], we determined the chemopreventive effect of long‐term (chronic) administration of Bitter Melon Juice (
Lakshmi Sai Pratyusha Bugata   +7 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

open access: yesMedicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu   +2 more
wiley   +1 more source

RUNX1‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells

open access: yesCancer Science, Volume 117, Issue 11, Page 2938-2952, November 2026.
RUNX1 transcriptionally activates CPXM1, promotes EMT, and enhances the proliferation, invasion, and metastasis of gastric cancer cells. ABSTRACT Gastric cancer (GC) remains a leading cause of cancer‐related mortality worldwide, with current treatment strategies largely limited to surgery, chemotherapy, and targeted therapy.
Ping Jia   +8 more
wiley   +1 more source

MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER

open access: yes, 2016
The mucin 1 (MUC1) oncoprotein has been linked to the inflammatory response by promoting cytokine-mediated activation of the NF-κB pathway. The TGF-β-activated kinase 1 (TAK1) is an essential effector of proinflammatory NF-κB signaling that also ...
Raina, Deepak   +12 more
core   +1 more source

Home - About - Disclaimer - Privacy